This inventor holds 2 USPTO granted patents. Top assignee: Hanwha Chemical Corporation. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Su Yeon Ryu in Monoclonal Antibody Development
Introduction
Su Yeon Ryu is an accomplished inventor based in Daejeon, South Korea. She has made significant contributions to the field of biomedical research, particularly in the development of human monoclonal antibodies. With a total of 2 patents, her work focuses on innovative therapeutic solutions for inflammatory diseases and cancer.
Latest Patents
Ryu's latest patents include a human monoclonal antibody that specifically binds to VCAM-1 and a composition for treating inflammatory diseases or cancer. The first patent describes a human monoclonal antibody that shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cells. This antibody effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, demonstrating low immunogenicity. It is intended for the treatment of various conditions, including asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction, and transplant rejection.
The second patent details a human recombinant monoclonal antibody that also targets VCAM-1. This invention inhibits adhesion and transmigration between leukocytes and endothelial cells, providing a therapeutic composition for inflammatory diseases and cancer. The antibody shows a strong affinity to VCAM-1 on human endothelial cells, making it a promising candidate for preventing and treating conditions such as asthma, arthritis, transplant rejection, cardiovascular disease, and cancer.
Career Highlights
Su Yeon Ryu is currently associated with Hanwha Chemical Corporation, where she continues her research and development efforts. Her work has positioned her as a key figure in the advancement of monoclonal antibody therapies.
Collaborations
Ryu collaborates with notable colleagues, including Jung Tae Lee and Kyung Duk Moon, who contribute to her research initiatives and innovations.
Conclusion
Su Yeon Ryu's contributions to the field of monoclonal antibodies represent a significant advancement in therapeutic options for inflammatory diseases and cancer. Her innovative work continues to pave the way for future research and development in this critical area of medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile